Iminoral Oral Solution contains Ciclosporin at a concentration of 100 mg/ml, an immunosuppressive agent primarily used to prevent organ transplant rejection and to treat various autoimmune disorders. Ciclosporin acts by selectively inhibiting the activation of T-lymphocytes, thereby reducing the immune response that contributes to graft rejection and autoimmune inflammation. This oral solution formulation allows for precise dosing adjustments, facilitating individualized therapy in patients requiring immunosuppression. Iminoral is indicated for the prophylaxis of organ rejection in renal, hepatic, and cardiac transplant recipients, as well as for the management of severe active rheumatoid arthritis and psoriasis unresponsive to conventional therapies. The pharmacokinetics of Ciclosporin necessitate careful monitoring of blood levels to optimize therapeutic efficacy while minimizing toxicity. Common adverse effects include nephrotoxicity, hypertension, tremor, and increased susceptibility to infections. Caution is advised when co-administered with other nephrotoxic or immunosuppressive agents. Dose adjustments may be required in hepatic impairment. Iminoral Oral Solution should be administered under strict medical supervision with regular monitoring of renal function, blood pressure, and Ciclosporin plasma concentrations to ensure safe and effective treatment outcomes. Patient adherence to prescribed dosing schedules is critical to prevent rejection episodes or disease flares.